Incyte Corporation (NASDAQ:INCY) Stock Sees Movement of 14.10% on the Week

A number of other research firms have also recently weighed in on INCY. Piper Jaffray Companies reaffirmed a "neutral" rating and set a $124.00 price target on shares of Incyte in a research report on Monday, April 17th. Incyte now has a consensus rating of Buy and a consensus target price of $139.68. Royal Bank of Canada reissued an outperform rating and issued a $138.00 price target (up from $123.00) on shares of Incyte in a report on Tuesday, February 14th. Raymond James Financial, Inc. reiterated a hold rating on shares of Incyte in a research report on Monday, April 17th. Zacks Investment Research downgraded shares of Incyte from a "hold" rating to a "sell" rating in a research note on Wednesday, April 5th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $139.68.

Incyte Corporation (NASDAQ:INCY) and Whole Foods Market, Inc.

INCY has been trading in a bearish trend, based on the relative levels of its 50-day and 200-day simple moving averages. Many traders and investors view the 52-week high or low as an important factor in determining a stock's current value and predicting future price movement. Incyte Corporation has a 26.66B market cap and its past year revenues were 1.23B. Year to date is -43.44%, -62.57% over the last quarter, -66.51% for the past six months and -79.64% over the last 12 months. The biopharmaceutical company reported ($0.96) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.01. Incyte had a net margin of 14.71% and a return on equity of 50.38%. The firm had revenue of $384.08 million during the quarter, compared to analyst estimates of $359.19 million. Comparatively, Incyte Corporation posted earnings of $0.01 per share in the same quarter previous year.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by BBNS and is owned by of BBNS. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and worldwide copyright and trademark law.

WARNING: "BMO Capital Markets Increases Incyte Co". Hedge funds and other institutional investors own 92.62% of the company's stock. Additionally, Incyte Corporation (INCY) stock price has gone up by 3.42% over the last 20 trading days, and its price is -15.90% below the 52-week high. Following the transaction, the director now owns 3,677 shares of the company's stock, valued at $456,904.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The stock traded on unusually ascend volume of 3.57 Million comparing to the average volume of 2713.47 shares, completing picture of exact trends with uncompleted dots in volume over the norm. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.

Several institutional investors have recently modified their holdings of the stock. IFP Advisors Inc boosted its stake in shares of Incyte by 6.8% in the first quarter.

Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for Incyte Corporation the EPS stands at -0.96 for the previous quarter, while the analysts predicted the EPS of the stock to be -1, suggesting the stock exceeded the analysts' expectations. Janus Capital Management LLC raised its position in shares of Incyte by 21.8% in the first quarter. Emerald Acquisition Ltd. increased its position in Incyte by 36.0% in the third quarter.

Juno Therapeutics, Inc. (JUNO) stock moved with shift of 10.67% in the past week. FNY Partners Fund LP now owns 985 shares of the biopharmaceutical company's stock valued at $131,000 after buying an additional 965 shares during the period.

If you look at the company's income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, INCY earned gross profit of 508.49 Million, in 2015 726.78 Million gross profit, while in 2016 Incyte Corporation (INCY) produced 1.06 Billion profit.

Vanessa Coleman